

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 190

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣493佰萬元(NTD 493mn)

營業項目Business：

原料藥API (42.80%)

中間體Intermediate (43.68%)

特用化學品 Custom-made chemicals (13.52%)

公司概況 Outline

	Y2012	2013 Jan.- Apr.
歐洲Europe	41.74%	34.36%
美洲America	22.11%	24.39%
亞洲Asia	18.15%	26.46%
國內Taiwan	18.00%	14.79%
合計Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:
生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:
製劑中之有效成分 Treatable ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2012	2013 Jan.-Apr.
營收Sales	1,262,572	432,919
營業成本COGS	(864,684)	(298,920)
毛利Gross Profit	397,888	133,999
毛利率 GP Ratio	31.5%	31.0%
營業費用Operating Expenses	(146,039)	(49,809)
營業利益Operating Income	251,849	84,190
營業外損益Non-Operating In/Ex	(13,695)	(3,443)
稅前淨利 Net Profit before Tax	238,154	80,747
所得稅Income Tax	(43,705)	
稅後淨利Net Profit after Tax	194,449	

產品組合-Products


Y2011	%		Y2012	%		Y2013	%	Amount
Di-VaNa	24.51%		V.A.	18.66%		V.A.	16.15%	69,895,168
PGA	17.65%		PGA	16.61%		Di-VaNa	14.77%	63,962,953
V.A.	13.76%		Di-VaNa	15.97%		PGA	13.21%	57,174,869
PPON	10.70%		PPON	7.88%		PPON	5.67%	24,526,297
M85	5.25%		Pent-2	4.78%		LPF.Na	4.93%	21,328,269
Pent-2	3.73%		5-HMT	4.33%		P20	4.74%	20,507,658
DBS	3.08%		M85	3.89%		Pent-2	4.01%	17,344,469
M115	2.55%		DBS	2.73%		DBS	3.67%	15,886,688
M74	2.31%		M115	2.59%		5-HMT	3.46%	14,997,760
NBE	1.87%		M74	2.18%		MQR-85L	3.27%	14,154,000
Total	85.40%		Total	79.62%		Total	73.87%	

產品介紹Products



產品介紹Product

- **Divalproex Sodium (Di-Va)**




- ✓ 學名藥於2009推出
- ✓ 9個客戶

Generic came out in 2009
9 customers

產品介紹Product

Valproic Acid (VA)




✓ 17個客戶

17 customers

產品介紹Product

- Pyrogallolaldehyde (PGA) - Benserazide



✓治療帕金森氏症之中間體


Intermediate for Parkinson's Disease

✓2個客戶

2 customers

產品介紹Product

Propiophenone (PPON) - Bupropion



✓第一項產品

First product

✓15個客戶

15 customers


產品介紹Product

Pent-2

- ✓ 第二項產品
- ✓ 5個客戶

Pentobarbital Sodium

- ✓ 鎮定安眠用之原料藥
- ✓ 4個客戶
- ✓ 2011年開始銷售6佰萬
- ✓ 2012銷售額23佰萬



Second product
5 customers

API used as calmative
4 customers
6mn, starting in 2011.
23mn sales in 2012

產品介紹Product

Hydroxychloroquine


- ✓ 2011年開始銷售10.8佰萬 10.8 mn, starting in 2011
- ✓ 2012年銷售額33.6佰萬 33.6mn sales in 2012
- ✓ 治療風濕性關節炎原料藥(Hydroxychloroquine sulfate)
API : Hydroxychloroquine sulfate for rheumarthrititis
- ✓ 原料藥市場約20噸100 佰萬 API market: 20 MT, 100mn

Anti-inflammatory (Loxoprofen sodium)

- ✓ 2012年銷售5個客戶5佰萬 5 customers, 5 mn sales in 2012.
- ✓ 日本市場200-300公噸,200美金/公斤
Japan market:200-300MT at USD 200/kg

產品介紹Product

5-HMT – Ritonavir, Lopinavir



✓ 愛滋病藥物之中間體

For AIDS treatment

5-Wing– Ritonavir, Lopinavir

✓ 2012年開始銷售5.7佰萬

5.7mn, starting in 2012

✓ 愛滋病藥物之中間體

For AIDS treatment

產品介紹Product

Antidepressant (Duloxetine)

- ✓ 2013年底專利到期 Patent will expire in the end of 2013
- ✓ 2011銷售9.5佰萬予10個客戶
9.5 mn sales consisting of 10 customers in 2011
- ✓ 2012年銷售額8佰萬 8 mn sales in 2012
- ✓ 2011及2012年中間體S-MMAA分別銷售2佰萬及1佰萬
S-MMAA(Intermediate) : 2 mn in 2011, 1mn in 2012.
- ✓ 2010年美國市場製劑銷售值美金31億
USD 3.1 billion in formulation in America in 2010

產品介紹Product

- ✓ 4-CPE
- ✓ Cyclophosphamide: 高效能原料藥
- Cyclophosphamide: high-potent API



GMP Status(GMP現況)

<i>API</i>	<i>CGMP certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Probucol	2004		2004		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011				
Duloxetine Hydrochloride	2012		2010/2011		
Thiopental acid	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013				
Clindamycin Palmitate HCl			2011		
Cyclophosphamide			2012		

簡報完畢



敬請指教